H1B Salary Data

Home › Employers › ABBA Biotech Corp.

ABBA Biotech Corp.: H-1B salaries and sponsorship

ABBA Biotech Corp. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: —.

Applications (LCAs)4
Certified2
Employer addressCupertino, CA
H-1B dependent employerNo

Does ABBA Biotech Corp. sponsor H-1B visas?

ABBA Biotech Corp. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Oct 25, 2023. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Special Effect, Marketing and Sale Manager3—
Director, Product Sales, Sound and Visual Effect1—

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20244—

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Director, Product Sales, Sound and Visual Effect$89,440–$91,520
part-time · Level I
Cupertino, CAOct 25, 2023Nov 30, 2023Certified
Special Effect, Marketing and Sale Manager$89,440–$91,520
part-time · Level I
Cupertino, CAOct 24, 2023Nov 30, 2023Certified
Special Effect, Marketing and Sale Manager$89,440–$91,520
part-time · Level I
Cupertino, CAOct 20, 2023Nov 30, 2023Denied
Special Effect, Marketing and Sale Manager$89,440–$91,520
Level I
Cupertino, CAOct 20, 2023Nov 30, 2023Denied

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).